Details for New Drug Application (NDA): 206876
✉ Email this page to a colleague
NDA 206876 describes VALGANCICLOVIR HYDROCHLORIDE, which is a drug marketed by Actavis Labs Fl Inc, Ajanta Pharma Ltd, Appco, Aurobindo Pharma, Granules, Hetero Labs Ltd V, MSN, Aurobindo Pharma Ltd, Cipla, Dr Reddys, Pharmobedient, Somerset Theraps Llc, Sph Zhongxi Pharm, and Strides Pharma Intl, and is included in seventeen NDAs. It is available from eighteen suppliers. Additional details are available on the VALGANCICLOVIR HYDROCHLORIDE profile page.
The generic ingredient in VALGANCICLOVIR HYDROCHLORIDE is valganciclovir hydrochloride. There are seventeen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the valganciclovir hydrochloride profile page.
The generic ingredient in VALGANCICLOVIR HYDROCHLORIDE is valganciclovir hydrochloride. There are seventeen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the valganciclovir hydrochloride profile page.
Summary for 206876
| Tradename: | VALGANCICLOVIR HYDROCHLORIDE |
| Applicant: | Dr Reddys |
| Ingredient: | valganciclovir hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 206876
| Mechanism of Action | DNA Polymerase Inhibitors |
Suppliers and Packaging for NDA: 206876
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| VALGANCICLOVIR HYDROCHLORIDE | valganciclovir hydrochloride | TABLET;ORAL | 206876 | ANDA | Dr. Reddy's Laboratories Inc | 43598-356 | 43598-356-30 | 30 TABLET in 1 BOTTLE (43598-356-30) |
| VALGANCICLOVIR HYDROCHLORIDE | valganciclovir hydrochloride | TABLET;ORAL | 206876 | ANDA | Dr. Reddy's Laboratories Inc | 43598-356 | 43598-356-60 | 60 TABLET in 1 BOTTLE (43598-356-60) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 450MG BASE | ||||
| Approval Date: | Dec 12, 2017 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
